Ruxolitinib takes center stage for VEXAS syndrome

Blood. 2022 Aug 25;140(8):807-808. doi: 10.1182/blood.2022017056.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Janus Kinase Inhibitors*
  • Nitriles
  • Pyrazoles / therapeutic use
  • Pyrimidines
  • Retrospective Studies

Substances

  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib